Michael M Goldberg insider trades: Navidea Biopharmaceuticals (NAVB) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
and 1 more company
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 14, 2014 | NAVB | ↑ Buy | 100,000 | $1.08 | $108K | Direct | Nov 17, 2014 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael M Goldberg's insider trades
Michael M Goldberg is President & CEO at Navidea Biopharmaceuticals (NAVB). Since Nov 14, 2014, Michael has reported 1 open-market purchase worth $108K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (22 filings), other transactions (4 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NAVB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.